Zacks Research Has Weak Outlook for Haemonetics Q1 Earnings

Haemonetics Co. (NYSE:HAE - Free Report) - Investment analysts at Zacks Research cut their Q1 2026 earnings per share (EPS) estimates for shares of Haemonetics in a report issued on Thursday, June 5th. Zacks Research analyst R. Department now expects that the medical instruments supplier will post earnings of $1.01 per share for the quarter, down from their prior estimate of $1.03. The consensus estimate for Haemonetics' current full-year earnings is $4.55 per share. Zacks Research also issued estimates for Haemonetics' Q2 2026 earnings at $1.16 EPS, FY2026 earnings at $4.84 EPS, Q2 2027 earnings at $1.31 EPS, FY2027 earnings at $5.41 EPS and FY2028 earnings at $6.02 EPS.

Haemonetics (NYSE:HAE - Get Free Report) last issued its earnings results on Thursday, May 8th. The medical instruments supplier reported $1.24 earnings per share for the quarter, topping analysts' consensus estimates of $1.22 by $0.02. Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. The company had revenue of $330.60 million for the quarter, compared to analysts' expectations of $329.38 million. During the same period in the prior year, the company earned $0.90 earnings per share. The firm's revenue was down 3.5% compared to the same quarter last year.

Other equities analysts have also issued reports about the company. JMP Securities reaffirmed a "market outperform" rating and set a $100.00 target price on shares of Haemonetics in a report on Tuesday, May 20th. Needham & Company LLC lowered their price objective on Haemonetics from $104.00 to $84.00 and set a "buy" rating for the company in a research note on Thursday, May 8th. Raymond James reaffirmed a "strong-buy" rating and issued a $105.00 target price (down from $115.00) on shares of Haemonetics in a research report on Friday, May 9th. Finally, Wall Street Zen downgraded shares of Haemonetics from a "buy" rating to a "hold" rating in a report on Tuesday, May 13th. One analyst has rated the stock with a sell rating, two have given a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $97.89.

Haemonetics Stock Performance

HAE traded down $0.22 on Monday, hitting $71.29. 368,555 shares of the company's stock were exchanged, compared to its average volume of 679,908. The company has a current ratio of 3.97, a quick ratio of 2.55 and a debt-to-equity ratio of 1.35. The stock has a fifty day moving average of $64.63 and a two-hundred day moving average of $69.42. Haemonetics has a twelve month low of $55.30 and a twelve month high of $94.99. The firm has a market cap of $3.42 billion, a PE ratio of 28.07, a P/E/G ratio of 1.11 and a beta of 0.36.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of HAE. TD Waterhouse Canada Inc. bought a new position in Haemonetics in the 4th quarter valued at about $25,000. Quarry LP lifted its stake in shares of Haemonetics by 63.4% in the 1st quarter. Quarry LP now owns 495 shares of the medical instruments supplier's stock worth $31,000 after acquiring an additional 192 shares during the period. Covestor Ltd boosted its holdings in shares of Haemonetics by 146.8% in the fourth quarter. Covestor Ltd now owns 738 shares of the medical instruments supplier's stock valued at $58,000 after acquiring an additional 439 shares in the last quarter. Whittier Trust Co. acquired a new position in shares of Haemonetics during the fourth quarter valued at approximately $62,000. Finally, University of Texas Texas AM Investment Management Co. bought a new stake in Haemonetics during the first quarter worth approximately $65,000. 99.67% of the stock is owned by institutional investors and hedge funds.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.